Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline.
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryMetabolomics and Type 2 Diabetes: Translating Basic Research into Clinical ApplicationComplications and challenges associated with polycystic ovary syndrome: current perspectivesTherapeutic Use of Metformin in Prediabetes and Diabetes PreventionHealth disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statementNaturopathic physicians: holistic primary care and integrative medicine specialists.Screening premorbid metabolic syndrome in community pharmacies: a cross-sectional descriptive study.Are we losing the battle against cardiometabolic disease? The case for a paradigm shift in primary prevention.Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guidelineHypertension in obese type 2 diabetes patients is associated with increases in insulin resistance and IL-6 cytokine levels: potential targets for an efficient preventive interventionPrevalence of metabolic syndrome and its correlated factors among children and adolescents of Ahvaz aged 10 - 19.Detecting type 2 diabetes and prediabetes among asymptomatic adults in the United States: modeling American Diabetes Association versus US Preventive Services Task Force diabetes screening guidelinesEndocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse.The Reversal Intervention for Metabolic Syndrome (TRIMS) study: rationale, design, and baseline data.Prevalence of metabolic syndrome among Hispanics/Latinos of diverse background: the Hispanic Community Health Study/Study of Latinos.Light physical activity determined by a motion sensor decreases insulin resistance, improves lipid homeostasis and reduces visceral fat in high-risk subjects: PreDiabEx study RCT.Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines.Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes?Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome.Longterm management of Polycystic Ovarian Syndrome (PCOS)The association of metabolic syndrome and urolithiasisIs the endocrine research pipeline broken? A systematic evaluation of the Endocrine Society clinical practice guidelines and trial registration.One risk assessment tool for cardiovascular disease, type 2 diabetes, and chronic kidney diseaseInflammation as a Link between Obesity and Metabolic Syndrome.Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity.Metabolic syndrome does not improve the prediction of 5-year cardiovascular disease and total mortality over standard risk markers. Prospective population based study.Metabolic syndrome and its correlated factors in an urban population in South West of Iran.Utility of the U.S. Preventive Services Task Force criteria for diabetes screeningHypocaloric diet supplemented with probiotic cheese improves body mass index and blood pressure indices of obese hypertensive patients--a randomized double-blind placebo-controlled pilot study.Ethnic and gender susceptibility to metabolic riskPrediabetes: the importance of early identification and intervention.COPD and associated comorbidities: a review of current diagnosis and treatment.The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis.Metformin in women with PCOS, cons.Performance of a multi-marker diabetes risk score in the Insulin Resistance Atherosclerosis Study (IRAS), a multi-ethnic US cohort.Update on blood pressure control and renal outcomes in diabetes mellitus.Cardiovascular risk factor associations in adults with psychosis and adults in a national comparator sample.The development of a patient care center in a supermarket chain pharmacy.Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms.
P2860
Q22241786-0165C524-AC1E-4553-A91A-6B1D879E96EDQ26774386-AF6E894F-ED52-45E7-BC5F-339920E74F94Q26799566-01A958F4-8717-4B86-830E-C56A0BCC7344Q26822066-D35FCDB4-341D-4695-922B-48DB890A4DB3Q28388174-2D96AABE-829F-48B5-8EA6-F0B90EE3E847Q30414453-1009617D-DFE4-4304-AD46-FF10361B95C1Q31162135-1375B18C-7579-4AF2-A669-C0C96952BD41Q33411079-C41385FA-5EB7-48D7-9C46-559718F129CCQ33587845-5DB19084-79D6-443D-BD54-AFCA83DAA8F0Q33627932-012B695F-9416-4645-B9B9-F8B906ED350DQ33653570-70A0D08B-1F8B-41B7-9B98-7B2583E3C77EQ33712222-01A21A10-987E-45B3-AB1A-A12C49584231Q33848311-8EF1889C-CA40-41B4-A540-786571D5310DQ33889954-90254D38-F4C8-405E-872F-2F6B5DBD1CC7Q33960218-FF994BBD-5DA3-499A-A408-1B8896256ABBQ34018090-BBBF4DE1-1A19-41F2-BBDC-29936CAE4600Q34542774-3FBD9867-C6CA-4302-BC50-0B09EA763025Q34631033-600CB6B2-C8D4-45E8-8F29-3B20132E6DE0Q34718312-51E4267D-97EB-435E-BD82-66FB8F51E791Q34926247-A49943D5-2712-4D39-B72A-E8ECCAD09776Q35200094-C277C8F2-F7E5-4568-9B88-9D973CAF02A4Q35271466-3892D8F6-53C3-4F47-B8C7-E9DFCDF1B116Q35743293-F51AF157-9B86-4AB8-B22C-1277FE786275Q35841153-44D5A529-C2AB-484A-880A-7F9EE18AEB14Q35864675-4888EBC9-5A7E-4C61-9EAC-864113D74179Q36047225-13B66484-89AD-439F-928E-1EB98460CC1DQ36152722-4A2AEF34-AF9C-42F5-91D4-371EA6B3B028Q36686320-C4B5DBD9-AAA1-4F8B-8907-36CE3EE26A3AQ37118979-9480DFEB-78EB-443C-884D-8642C3305CF5Q37367413-666423F8-9503-4C46-82E6-1725AC3EF285Q37604450-ABAB5FA7-7B6E-45F4-8366-C69D90A03FFBQ37777010-E864D9B5-4476-49D0-9C2C-859A525368CCQ38036786-4A68B61C-A28C-4BB6-BB61-D8AF3BF89227Q38056783-4D1AB208-BA4B-4A27-87C1-F1566FA3E821Q38245312-FB187C5A-5ED5-4487-9353-C54C8ACA7E33Q38404230-C69FBAC8-8B70-47F3-B3D9-8C3624B309FDQ38492248-7E14C3AB-3330-4358-97AC-2EBBE168218BQ39059294-3A12C821-3320-4642-B178-685F206D64C6Q39578244-ECDF2580-91A7-4A51-98C0-2E9D35E839B6Q39658839-8AE27222-655C-4091-8F6D-1E9E86FE263E
P2860
Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Primary prevention of cardiova ...... y clinical practice guideline.
@en
Primary prevention of cardiova ...... y clinical practice guideline.
@nl
type
label
Primary prevention of cardiova ...... y clinical practice guideline.
@en
Primary prevention of cardiova ...... y clinical practice guideline.
@nl
prefLabel
Primary prevention of cardiova ...... y clinical practice guideline.
@en
Primary prevention of cardiova ...... y clinical practice guideline.
@nl
P2093
P356
P1476
Primary prevention of cardiova ...... ty clinical practice guideline
@en
P2093
Edward S Horton
Ele Ferrannini
Endocrine Society
Robert J Heine
Ryuzo Kawamori
Scott M Grundy
Steven M Haffner
P304
P356
10.1210/JC.2008-0222
P407
P577
2008-07-29T00:00:00Z